Informational Webinar:
Collaborative Advancement of Cures for T1D

November 9, 2022

Joshua A. Vieth, PhD
Director, Research

Karen Ng
Senior Program Administrator
Introduction

Esther Latres, PhD
Vice President, Research
JDRF International
JDRF’s Purpose

**Our Vision:**
A world without T1D

**Our Mission:**
Improving lives today and tomorrow by accelerating life-changing breakthroughs to cure, prevent and treat T1D and its complications.
JDRF Drives Research

JDRF has built a team of in-house researchers whose collective knowledge of the T1D field is unsurpassed

- Partner with leading T1D researchers, institutions, and experts around the world
- Bring other top researchers into the T1D field
- Direct and drive research across a strategic portfolio of work
- Continually seek out new opportunities and creative partnerships
- Support advances through grant funding, investments, and partnerships

JDRF has played a key role in every major T1D advance – drug, device, or cell research, made in the last 50 years.
JDRF Affects Every Step in the Pipeline

T1D Therapy Development

- Discovery Research
  - Fund Research
  - Advocate for Government Funding of Research
  - Invest Alongside For-Profit Funders in T1D Products
  - Advance Clinical Trials

T1D Therapy Access

- Translational Research
- Regulatory Approval
  - Improve Prospects for Regulatory Approval
- Healthcare Coverage
  - Increase Coverage, Affordability, and Choice
- Clinical Adoption
  - Support Continuing Healthcare Provider Education
  - Education Community

Better Outcomes
Therapies for Every Stage of T1D

Insulin Production:
Stage 1  Stage 2  Stage 3  Established

Screening  Disease Modifying Therapies  Cell Therapy
Current Funding Opportunity

Collaborative Advancement of Cures for T1D

- Bold advancement of therapies for all stages of disease requires significant resources as well as broad technological, subject-matter, and analytical expertise.

- Research plans to move us closer to safe, effective, therapies and cures for T1D likely need more expertise than is available in one laboratory or that can be funded by one grant award.

- Therefore, JDRF call for proposals that outline high-impact research by coordinated, multidisciplinary teams.

- Applicants to be considered are established or newly formed collaborative teams consisting of 2 or more laboratories with unique yet complementary expertise to address major gaps in the field.
Structure of the RFA

- Collaborative teams of 2-3 (or more) laboratories or research entities.
- Teams should identify a primary investigator and institution to serve as the lead applicant.
- Teams can be composed of collaborative groups of academic researchers, companies, or a combination of the two.

Budgeting Guidelines:
- Proposed budgets should be based upon up to three years of research.
- Partnerships containing two laboratories/partners may request up to $500,000.00 per year (for a 3-year total of $1.5M).
- Partnerships containing three or more laboratories/partners may request up to $750,000.00 per year (for a 3-year total of $2.25M).
- Funds may be distributed among partners as needed for the scope of the work, and do not have to be divided equally.

<table>
<thead>
<tr>
<th>LOI Deadline</th>
<th>Notification of LOI Outcome</th>
<th>Full Proposal Deadline</th>
<th>Award Notification</th>
<th>Earliest Anticipated Start Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 8, 2022</td>
<td>December 22, 2022</td>
<td>February 13, 2023</td>
<td>July 2023</td>
<td>September 2023</td>
</tr>
</tbody>
</table>
Applicant Eligibility

New or established teams of investigators with complementary expertise to facilitate bold advances toward a cure for T1D.

JDRF welcomes applications from all qualified individuals and encourages applications from members of groups underrepresented in the sciences.

Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent and have a faculty position or equivalent at a college, university, medical school, or other research facility.

Domestic and foreign non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, industry, units of state and local governments, and eligible agencies of the federal government

No citizen requirements for this program.
Project Eligibility

Work proposed should address the development and enabling of clinical testing of therapies and approaches toward one or more of the following JDRF Cures Program goals:

**Screening**
- The development of data and analysis necessary for improving the prediction of high-risk individuals

**Disease Modifying Therapies**
- Accelerating the advancement of therapies that delay, stop, or reverse the development and progression of T1D, and enable pivotal clinical testing of these therapies.
- Developing immunotherapy approaches that stop the autoimmune attack, enhance immune regulation, or deviate inflammatory processes.
- Investigating approaches focused on promoting the function, survival, regeneration, and targeted delivery of therapies to beta cells.

**Cell Therapy**
- Accelerating the development and validation of strategies that ensure cell survival and function in alternative sites of implantation.
- Research that enables the development of safe, more efficacious, and longer-lasting cell therapies without the use of broad immunosuppression.
Teams that combine the expertise of established investigators in the field of T1D with those outside of the field that provide the required expertise to expand the scope and capabilities of the proposed research are of high priority.

Priority consideration will be given to projects that outline research plans that are approaching clinical translation. Consideration will be given to clinical trials (but applicants must reach out to the scientific contact prior to submitting an LOI).

Priority consideration will be given to proposals that outline courses of study that address multiple Cures Program Strategies (for example, investigation into beta cell transplantation and immunotherapy to promote transplanted cell survival).

Given the expanded nature of the resources available for projects selected for funding under this announcement, priority will be given to proposals that outline accelerated and bold courses of research to potentiate significant advances toward a cure for T1D.
Examples of Possible Projects

Combining targeted immunotherapy to stop the autoimmune attack with specialized experience in beta cell transplantation.

Investigating therapies to stop the autoimmune attack by individual laboratories specializing in immunology, beta cell biology, and/or technical expertise such as scRNAseq or a humanized mouse model.

Combining expertise in screening with expertise in targeted immunotherapy.

Combining expertise in cell biology with expertise in that analysis approaches necessary for the creation and utilization of big data sets.

Combining expertise in islet transplantation with expertise in novel immunotherapies, including prediction of responders and non-responders to immunotherapy to identify patients most likely to benefit from treatment.

Combining expertise in beta cell health and stress and expertise in developing cell delivery systems that ensure adequate oxygenation and vascularization following transplantation in alternative sites.

Combining expertise in islet transplantation with novel immunotherapies to test and validate new protocols to eliminate the use of immunosuppressive drugs and reduce the risk to transplant patients.

Combining investigators with a therapeutic target or asset in development with investigators experienced in clinical translation.
Out of Scope

- Projects that focus solely on advancing/developing methodology or streamlining processes

- Studies focused solely on the development and/or broad phenotyping of animal models

- Studies that do not outline a clear transition from one development stage of research to the next (Discovery / Preclinical / Clinical)
Letter of Intent

Due December 8th, 2022

- Should be submitted online through the RMS360 portal
- 3 pages maximum for research outline
- Submission mechanism determined by collaborative group type:
  - Strategic Research Agreement (SRA)
    - For proposals with applicants/investigators at an academic institution or similar entity
  - Industry Development and Discovery Program (IDDP)
    - For proposals with applicants/investigators at an industry entity
  - JDRF strongly encourages collaborations between academic and industry institutions. Contact JDRF Staff if submitting a combined academic/industry proposal for guidance prior to preparing your LOI

Letters of Intent and Full Proposals (if invited) for this funding call must address the role and necessity of each individual investigator or research entity proposed as part of the collaborative team in the achievement of the research aims. If selected for a Full Proposal, a clear communication and coordination plan to facilitate the cooperative and multi-laboratory scope of the described research must be included. The distribution of budget across the institutions must be clearly described and justified.
Review Criteria

Significance

Relevance

Approach

Innovation

Environment

Appropriateness of Budget

Feasibility of Research Plan

Strength/Suitability/Synergy of Proposed Collaborative Team

Potential for Significant Advancement of T1D Research
Tips for Success

1) Familiarize yourself with the most recent T1D literature and the JDRF Research Strategy
2) No need to spend ½ page of 2-page LOI describing T1D, the prevalence of the disease, or the need for further developed therapies.
3) Familiarize yourself with the SRA/IDDP template and provide clear answers in each of the sections outlined.
4) Develop a collaborative team of researchers with complimentary areas of expertise that can each contribute to significant advancement of a focused research project.
5) Design your research plan to potentiate significant advancement toward enabling or conducting clinical testing
6) Don’t hesitate to contact JDRF staff with any questions during the submission process.
THANK YOU!

Any Questions?

Joshua A. Vieth, PhD  
Director, Research  
jvieth@jdrf.org

Karen Ng  
Senior Program Administrator  
kng@jdrf.org

https://grantcenter.jdrf.org